AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
This Quarter Return
+0.92%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$640M
AUM Growth
+$640M
(-0.69%)
Cap. Flow
+$2.06M
Cap. Flow
% of AUM
0.32%
Top 10 Holdings %
Top 10 Hldgs %
47.48%
Holding
103
New
14
Increased
22
Reduced
20
Closed
16
Top Buys
| 1 |
Apogee Therapeutics
APGE
|
$12.1M |
| 2 |
Merus
MRUS
|
$9.57M |
| 3 |
Arvinas
ARVN
|
$7.76M |
| 4 |
Spyre Therapeutics
SYRE
|
$7.59M |
| 5 |
ProQR Therapeutics
PRQR
|
$7.49M |
Top Sells
| 1 |
Kura Oncology
KURA
|
$13.4M |
| 2 |
Astria Therapeutics
ATXS
|
$7.98M |
| 3 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$7.86M |
| 4 |
Viridian Therapeutics
VRDN
|
$7M |
| 5 |
Madrigal Pharmaceuticals
MDGL
|
$5.4M |
Sector Composition
| 1 | Healthcare | 90.96% |
| 2 | Financials | 0.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Erasca
ERAS
$406M
| $6.27M | 0.84% |
2,499,431
| – | – |
|
27
Soleno Therapeutics
SLNO
$3.56B
| $5.84M | 0.78% |
130,000
+105,000
| +420% | +$4.72M |
|
28
Arrowhead Research
ARWR
$3.84B
| $5.64M | 0.76% |
300,000
-25,000
| -8% | -$470K |
|
29
BridgeBio Pharma
BBIO
$9.91B
| $5.49M | 0.74% |
200,000
-100,000
| -33% | -$2.74M |
|
30
Protagonist Therapeutics
PTGX
$3.62B
| $5.02M | 0.67% |
+130,000
| New | +$5.02M |
|
31
Mineralys Therapeutics
MLYS
$1.94B
| $4.31M | 0.58% |
350,000
| – | – |
|
32
Perspective Therapeutics
CATX
$251M
| $4.15M | 0.56% |
1,300,000
+800,000
| +160% | +$2.55M |
|
33
Avalo Therapeutics
AVTX
$139M
| $4.09M | 0.55% |
550,765
+505,765
| +1,124% | +$3.76M |
|
|
PCSC
34
Perceptive Capital Solutions Corp Class A Ordinary Shares
PCSC
$117M
| $3.56M | 0.48% |
350,000
| – | – |
|
35
Travere Therapeutics
TVTX
$1.75B
| $3.48M | 0.47% |
+200,000
| New | +$3.48M |
|
36
Insmed
INSM
$30.3B
| $3.45M | 0.46% |
50,000
| – | – |
|
37
NewAmsterdam Pharma Company N.V. Warrant
NAMSW
$64M
| $3.33M | 0.45% |
237,935
+24,961
| +12% | +$349K |
|
|
CMPS
38
Compass Pathways
CMPS
$452M
| $3.21M | 0.43% |
850,512
+550,000
| +183% | +$2.08M |
|
39
Cullinan Oncology
CGEM
$456M
| $3.21M | 0.43% |
263,817
| – | – |
|
|
40
Viridian Therapeutics
VRDN
$1.59B
| $3.06M | 0.41% |
159,614
-365,386
| -70% | -$7M |
|
41
Mirum Pharmaceuticals
MIRM
$3.75B
| $2.93M | 0.39% |
70,742
-4,258
| -6% | -$176K |
|
42
CG Oncology
CGON
$2.19B
| $2.87M | 0.38% |
+100,000
| New | +$2.87M |
|
|
TECX
43
Tectonic Therapeutic, Inc. Common Stock
TECX
$305M
| $2.69M | 0.36% |
58,331
| – | – |
|
|
BBOT
44
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$779M
| $2.63M | 0.35% |
250,000
| – | – |
|
|
OACCU
45
Oaktree Acquisition Corp. III Life Sciences Unit
OACCU
$191M
| $2.54M | 0.34% |
+250,000
| New | +$2.54M |
|
46
Immunovant
IMVT
$2.91B
| $2.48M | 0.33% |
100,000
-125,000
| -56% | -$3.1M |
|
|
JBIO
47
Jade Biosciences, Inc. Common Stock
JBIO
$245M
| $2.12M | 0.28% |
22,857
+5,714
| +33% | +$530K |
|
48
Vaxcyte
PCVX
$4.17B
| $2.05M | 0.27% |
25,000
-25,000
| -50% | -$2.05M |
|
49
Nkarta
NKTX
$149M
| $1.99M | 0.27% |
800,000
+150,000
| +23% | +$374K |
|
50
NextCure
NXTC
$13.3M
| $1.78M | 0.24% |
191,883
| – | – |
|